Northwestern Medicine researchers reported a safety concern for GLP-1 receptor agonists, linking the drugs to higher incidence of fainting and dizziness, per the provided content. The report frames the issue as hypotensive events and positions it as a clinical monitoring consideration for commonly prescribed weight and metabolic therapies. In parallel, another ENDO 2026 presentation summarized unexpected findings on changes in physical activity among adults using GLP-1 medications for weight loss, indicating potential downstream behavioral effects that could intersect with tolerability and overall outcomes. Together, the updates suggest clinicians may need to treat GLP-1 prescribing as a broader real-world safety and lifestyle question rather than only a glycemic or weight-centric decision.